Atlas Trials

A Phase II Study to Evaluate the Efficacy and the Safety of Flumatinib in CML-AP or CML-BP Patients

Clinical trial NCT02511340 · UNKNOWN

Trial details

NCT number
NCT02511340
Sponsor
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Chronic Myelogenous Leukemia
Start date
2013-01-01
Primary completion
2015-08-01
Enrollment
167

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.